Американское общество гирудотерапии

Contemporary device management of cardiogenic shock following acute myocardial infarction

Review published in Heart failure reviews (2021)

Последнее обновление: June 18, 2026Рецензент: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewРазработка лекарственных препаратовSuleiman T et al. · Heart failure reviews, 2021

Abstract

Despite advances in the overall management of acute myocardial infarction (AMI), cardiogenic shock in the setting of AMI (CS-AMI) continues to be associated with poor patient outcomes. There are multiple devices that can be used in CS-AMI to support the failing circulation, although their utility in improving outcomes as compared with conventional pharmacotherapy of vasopressors and inotropes remains to be established. This contemporary review provides an update on the evidence base for each of these techniques. In CS-AMI, acute thrombotic occlusion of a major epicardial artery leads to hypoxia and myocardial ischaemia in the territory subtended by that vessel. The resultant regional dysfunction in myocardial contractility can severely compromise stroke volume and result in acute circulatory failure, systemic hypoperfusion, lactic acidosis, multi-organ failure and ultimately death.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsHeart-Assist DevicesHumansIntra-Aortic Balloon PumpingMyocardial InfarctionShock, CardiogenicStroke VolumeTreatment Outcome

Резюме

Despite advances in the overall management of acute myocardial infarction (AMI), cardiogenic shock in the setting of AMI (CS-AMI) continues to be associated with poor patient outcomes.

Почему это важно для гирудотерапии

This review provides an update on the evidence base for multiple devices used to support the failing circulation in cardiogenic shock complicating acute myocardial infarction (CS-AMI), comparing their utility against conventional pharmacotherapy of vasopressors and inotropes. The abstract describes the pathophysiology of CS-AMI, noting that acute thrombotic occlusion of a major epicardial artery can lead to circulatory failure, systemic hypoperfusion, lactic acidosis, multi-organ failure, and death, and that outcomes remain poor despite advances in management. This review makes no mention of leeches, hirudin, leech therapy, or the leech secretome. Caveat: it has no identifiable relevance to hirudotherapy or ASH's domain.

Цитирование

Contemporary device management of cardiogenic shock following acute myocardial infarction

Suleiman T et al. · Heart failure reviews, 2021

Связанный клинический контекст

Узнайте, как это исследование связано с клинической практикой

Добавлено в библиотеку ASH: May 27, 2026 · Последнее обновление сайта: June 18, 2026

Этот сайт предоставляет образовательную информацию и не является медицинской консультацией, диагнозом или рекомендацией по лечению. Гирудотерапия сопряжена с клинически значимыми рисками и должна проводиться только квалифицированными клиницистами в рамках институционально утверждённых протоколов. Разрешение FDA 510(k) для медицинских пиявок ограничено определёнными показаниями; обсуждения исследовательского и нелицензионного применения отмечены соответствующим образом. Для индивидуальных медицинских рекомендаций обратитесь к квалифицированному медицинскому специалисту.